Keywords: Atrial fibrillation, Markt, Boehringer Ingelheim, Pradaxa, Bayer, Johnson & Johnson, Xarelto, Bristol-Myers, fizer, apixaban, Sanofi-Aventis, Multaq, Decision Resoruces
Novel oral anticoagulants and anti-arrhythmic agents will drive atrial fibrillation drug market to increase more than eight-fold to $6.8 billion
Article | 09 July 2010
The launch and uptake of novel oral anticoagulants and anti-arrhythmic agents - specifically, drugs from Boehringer Ingelheim, Bayer/Johnson & ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
